1. Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma
   Danijela Drakulic et al, 2022, Cells CrossRef
2. Chrysomycin A Inhibits the Proliferation, Migration and Invasion of U251 and U87-MG Glioblastoma Cells to Exert Its Anti-Cancer Effects
   Dong-Ni Liu et al, 2022, Molecules CrossRef
3. null
   Alexander E. Braley et al, 2022 CrossRef
4. Prognostic biomarker prediction for glioma induced by heavy metals and their mixtures: An in-silico study
   Hai Duc Nguyen, 2022, Toxicology and Applied Pharmacology CrossRef
5. Transcriptome and single-cell analysis reveal the contribution of immunosuppressive microenvironment for promoting glioblastoma progression
   Lulu Ni et al, 2023, Front. Immunol. CrossRef
6. Role of Basic Fibroblast Growth Factor in Cancer: Biological Activity, Targeted Therapies, and Prognostic Value
   Alessio Ardizzone et al, 2023, Cells CrossRef
7. Long non-coding RNA in glioblastoma invasion: Angiogenesis and mesenchymal transition via PI3K and Wnt signalling
   Dexter Hoi Long Leung, 2023, APJMBB CrossRef
8. Genome-wide profiling of patient-derived glioblastoma stem-like cells reveals recurrent genetic and transcriptomic signatures associated with brain tumors
   Elisabetta Lazzarini et al, 2023, J Neurooncol CrossRef
9. Multiple therapeutic approaches of glioblastoma multiforme: From terminal to therapy
   Smita Kumari et al, 2023, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
10. Combining Pr3+-Doped Nanoradiosensitizers and Endogenous Protoporphyrin IX for X-ray-Mediated Photodynamic Therapy of Glioblastoma Cells
    Gabrielle A. Mandl et al, 2023, ACS Appl. Bio Mater. CrossRef
11. Conditional generation of free radicals by selective activation of alkoxyamines: towards more effective and less toxic targeting of brain tumors
    Patricia Piris et al, 2023, Chem. Sci. CrossRef
12. IRP1 mediated ferroptosis reverses temozolomide resistance in glioblastoma via affecting LCN2/FPN1 signaling axis depended on NFKB2
    Yufei Lan et al, 2023, iScience CrossRef
13. Translocator protein (18kDA) (TSPO) marks mesenchymal glioblastoma cell populations characterized by elevated numbers of tumor-associated macrophages
    Lorraine Weidner et al, 2023, acta neuropathol commun CrossRef
14. Non-coding RNAs (ncRNAs) and Multidrug Resistance in Glioblastoma: Therapeutic Challenges and Opportunities
    Gehad Mohammed Subaiea et al, 2023, Pathology - Research and Practice CrossRef
15. Results of treatment of recurrent growth and metastasis of anaplastic gliomas
    S. K. Badu et al, 2023, Bulletin of Neurology, Psychiatry and Neurosurgery CrossRef
16. Furanocoumarins as Enhancers of Antitumor Potential of Sorafenib and LY294002 toward Human Glioma Cells In Vitro
    Joanna Sumorek-Wiadro et al, 2024, IJMS CrossRef
17. Early investigation of a novel SI306 theranostic prodrug for glioblastoma treatment
    Chiara Vagaggini et al, 2024, Drug Development Research CrossRef
18. Glioblastoma Therapy: Past, Present and Future.
    Elena Obrador et al, 2024, Int J Mol Sci CrossRef
19. STAT3 phosphorylation inhibitor Bt354 exhibits anti‐neoplastic activity in glioblastoma multiforme cells
    Yi‐Chun Chiang et al, 2024, Environmental Toxicology CrossRef
20. CD133 significance in glioblastoma development: in silico and in vitro study
    Mahdi Abdoli Shadbad et al, 2024, Eur J Med Res CrossRef
21. Glioblastoma: An Update in Pathology, Molecular Mechanisms and Biomarkers.
    Zhong Lan et al, 2024, Int J Mol Sci CrossRef
22. Harnessing the potential of nanoengineered siRNAs carriers for target responsive glioma therapy: Recent progress and future opportunities
    Kailash Ahirwar et al, 2024, International Journal of Biological Macromolecules CrossRef
23. PCSK5 downregulation promotes the inhibitory effect of andrographolide on glioblastoma through regulating STAT3
    Huiyuan Gong et al, 2024, Mol Cell Biochem CrossRef
24. Identification of Novel Molecular and Clinical Biomarkers of Survival in Glioblastoma Multiforme Patients: A Study Based on The Cancer Genome Atlas Data
    Luísa Esteves et al, 2024, BioMed Research International CrossRef
25. A review of natural products and small‐molecule therapeutics acting on central nervous system malignancies: Approaches for drug development, targeting pathways, clinical trials, and challenges
    Ardalan Pasdaran et al, 2024, Drug Development Research CrossRef
26. Identification of candidate biomarkers for GBM based on WGCNA
    Qinghui Sun et al, 2024, Sci Rep CrossRef
27. Targeting inflammation in glioblastoma: An updated review from pathophysiology to novel therapeutic approaches
    Nasser M. Alorfi et al, 2024 CrossRef
28. A comprehensive survey on the use of deep learning techniques in glioblastoma
    Ichraq El Hachimy et al, 2024, Artificial Intelligence in Medicine CrossRef
29. Survival rate of patient with glioblastoma: a population-based study
    Masih Sabouri et al, 2024, Egypt J Neurosurg CrossRef
30. IDH1-mutant metabolite D-2-hydroxyglutarate inhibits proliferation and sensitizes glioma to temozolomide via down-regulating ITGB4/PI3K/AKT
    Shuangmei Tong et al, 2024, Cell Death Discov. CrossRef
31. Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme—A Literature Review and Clinical Outcomes
    Marcin Jezierzański et al, 2024, Current Oncology CrossRef
32. A Novel Strategy for Glioblastoma Treatment by Natural Bioactive Molecules Showed a Highly Effective Anti-Cancer Potential
    Alessandro Giammona et al, 2024, Nutrients CrossRef
33. Immunomodulatory signalling networks in glioblastoma multiforme: a comprehensive review of therapeutic approaches
    Souhrid Sarkar et al, 2024, Human Cell CrossRef
34. Chemical composition of essential and fixed oils of Tagetes erecta fruits (Iran) and their implications in inhibition of cancer signaling
    Vahideh Ahmadpour et al, 2024, Sci Rep CrossRef
35. The potential of exosomes as a new therapeutic strategy for glioblastoma
    Leonor Cunha Silva et al, 2024, European Journal of Pharmaceutics and Biopharmaceutics CrossRef
36. CEP-1347 Boosts Chk2-Mediated p53 Activation by Ionizing Radiation to Inhibit the Growth of Malignant Brain Tumor Cells
    Yuta Mitobe et al, 2024, IJMS CrossRef
37. Regulation of autophagy by non-coding RNAs in human glioblastoma
    Mehran Molavand et al, 2024, Med Oncol CrossRef
38. Harnessing the role of aberrant cell signaling pathways in glioblastoma multiforme: a prospect towards the targeted therapy
    Subbrina Hasan et al, 2024, Mol Biol Rep CrossRef
39. Exploring therapeutic potentials of Tridax procumbens for Glioma: An in-silico approach employed network pharmacology, molecular docking, and molecular dynamics simulation
    Acharya Balkrishna et al, 2024, South African Journal of Botany CrossRef
40. Prognosis prediction via histological evaluation of cellular heterogeneity in glioblastoma
    Mari Kirishima et al, 2024, Sci Rep CrossRef
41. Novel strategies to overcome chemoresistance in human glioblastoma
    Qing Tang et al, 2024, Biochemical Pharmacology CrossRef
42. null
    Koustav Mohapatra et al, 2025 CrossRef
43. HOXD9 Enhances the Release of HMGB1 and Boosts Glycolysis in Glioblastoma under Hypoxic Conditions, Leading to Tumor Growth by Activating the Transcription of PFKFB3
    Guangzhi Xu et al, 2024, Front. Biosci. (Landmark Ed) CrossRef
44. MiR-433 inhibits cell invasion of glioblastoma via direct targeting TRPM8 based on bioinformatic analysis and experimental validation
    Jianping Zeng et al, 2024, Gene CrossRef
45. Nanotherapeutic strategy against glioblastoma using enzyme inhibitors
    Rekha Thiruvengadam et al, 2024, Biomedicine & Pharmacotherapy CrossRef
46. Genomic Profiling in Glioma Patients to Explore Clinically Relevant Markers
    Viacheslav Varachev et al, 2024, IJMS CrossRef
47. Role of Podoplanin (PDPN) in Advancing the Progression and Metastasis of Glioblastoma Multiforme (GBM)
    Bharti Sharma et al, 2024, Cancers CrossRef
48. N-Glycoside of Indolo[2,3-a]pyrrolo[3,4-c]carbazole LCS1269 Exerts Anti-Glioblastoma Effects by G2 Cell Cycle Arrest and CDK1 Activity Modulation: Molecular Docking Studies, Biological Investigations, and ADMET Prediction
    Nikolay Kalitin et al, 2024, Pharmaceuticals CrossRef
49. Antitumor Effect of Butia odorata Hydroalcoholic Extract on C6 and U87MG Glioma Cell Lines: Impact on Redox Status and Inflammation Signaling
    Juliane Torchelsen Saraiva et al, 2025, Neurochem Res CrossRef
50. Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes
    David Sipos et al, 2025, Cancers CrossRef
51. Sesquiterpene Lactones as Promising Anti-Glioblastoma Drug Candidates Exerting Complex Effects on Glioblastoma Cell Viability and Proneural–Mesenchymal Transition
    Andrey V. Markov et al, 2025, Biomedicines CrossRef
52. A Theoretical Study on the Efficacy and Mechanism of Combined YAP-1 and PARP-1 Inhibitors in the Treatment of Glioblastoma Multiforme Using Peruvian Maca Lepidium meyenii
    Albert Turpo-Peqqueña et al, 2025, CIMB CrossRef
53. null
    Fuad Al Abir et al, 2024 CrossRef
54. Targeting JAK/STAT3 in glioblastoma cells using an alginate-PNIPAm molecularly imprinted hydrogel for the sustained release of ruxolitinib
    Alexandra-Iulia Bărăian et al, 2025, International Journal of Biological Macromolecules CrossRef
55. An Effective Method to Identify Cooperation Driver Gene Sets
    Wei Zhang et al, 2025, CBIO CrossRef
56. The role of lncRNAs in the interplay of signaling pathways and epigenetic mechanisms in glioma
    Can Bora Yildiz et al, 2025, Epigenomics CrossRef